PDF(Pubmed)
Abstract：
BACKGROUND: We assessed experiences of human papillomavirus (HPV) vaginal self-sampling and future screening preferences in an ethnically and socio-economically diverse group of women overdue for cervical screening.
METHODS: A postal questionnaire was embedded in the YouScreen self-sampling trial in England: 32.5% (2712/8338) of kit completers returned the survey. Kit non-completers were encouraged to return a questionnaire, but no responses were received. Participants were ethnically diverse (40.3% came from ethnic minority backgrounds), and 59.1% came from the two most deprived quintiles. Differences in confidence in kit completion, trust in the test results and intention to attend a follow-up test if HPV-positive were evaluated using Pearson\'s χ2 analyses. Binary logistic regression models explored predictors of a future screening choice and preferences for urine versus vaginal self-sampling.
RESULTS: Most kit-completers reported high confidence in self-sampling (82.6%) and high trust in the results (79.9%), but experiences varied by ethnicity and screening status. Most free-text comments were positive but some reported difficulties using the device, pain or discomfort. Most women would opt for self-sampling in the future (71.3% vs. 10.4% for a clinician-taken test) and it was more often preferred by ethnic minority groups, overdue screeners and never attenders. Urine self-tests were preferred to vaginal tests (41.9% vs. 15.4%), especially among women from Asian, Black or Other Ethnic backgrounds.
CONCLUSIONS: Kit-completers were confident, found the test easy to complete, and trusted the self-sample results. However, experiences varied by ethnic group and some women highlighted difficulties with the kit. Most women would prefer self-sampling in the future, but it was not a universal preference, so offering a choice will be important.
UNASSIGNED: We did not have direct patient and public involvement and engagement (PPIE) in the questionnaire design. However, patients and public representatives did input into the design of the YouScreen trial and reviewed the wider study materials (e.g. participant information sheet).
BACKGROUND: This questionnaire study was embedded in the YouScreen trial. The protocol for the YouScreen trial is available at https://www.isrctn.com/ISRCTN12759467. The National Institute for Health Research 43 Clinical Research Network (NIHR CRN) Central Portfolio Management System (CPMS) ID is 4441934.
METHODS: A postal questionnaire was embedded in the YouScreen self-sampling trial in England: 32.5% (2712/8338) of kit completers returned the survey. Kit non-completers were encouraged to return a questionnaire, but no responses were received. Participants were ethnically diverse (40.3% came from ethnic minority backgrounds), and 59.1% came from the two most deprived quintiles. Differences in confidence in kit completion, trust in the test results and intention to attend a follow-up test if HPV-positive were evaluated using Pearson\'s χ2 analyses. Binary logistic regression models explored predictors of a future screening choice and preferences for urine versus vaginal self-sampling.
RESULTS: Most kit-completers reported high confidence in self-sampling (82.6%) and high trust in the results (79.9%), but experiences varied by ethnicity and screening status. Most free-text comments were positive but some reported difficulties using the device, pain or discomfort. Most women would opt for self-sampling in the future (71.3% vs. 10.4% for a clinician-taken test) and it was more often preferred by ethnic minority groups, overdue screeners and never attenders. Urine self-tests were preferred to vaginal tests (41.9% vs. 15.4%), especially among women from Asian, Black or Other Ethnic backgrounds.
CONCLUSIONS: Kit-completers were confident, found the test easy to complete, and trusted the self-sample results. However, experiences varied by ethnic group and some women highlighted difficulties with the kit. Most women would prefer self-sampling in the future, but it was not a universal preference, so offering a choice will be important.
UNASSIGNED: We did not have direct patient and public involvement and engagement (PPIE) in the questionnaire design. However, patients and public representatives did input into the design of the YouScreen trial and reviewed the wider study materials (e.g. participant information sheet).
BACKGROUND: This questionnaire study was embedded in the YouScreen trial. The protocol for the YouScreen trial is available at https://www.isrctn.com/ISRCTN12759467. The National Institute for Health Research 43 Clinical Research Network (NIHR CRN) Central Portfolio Management System (CPMS) ID is 4441934.
摘要：
背景：我们评估了人类乳头瘤病毒（HPV）阴道自我取样的经验，以及在种族和社会经济不同的女性群体中未来的筛查偏好。
方法：在英国的YouScreen自抽样试验中嵌入了邮政问卷：32.5％（2712/8338）的试剂盒完成者返回了调查。鼓励Kit非完成者返回问卷，但没有收到任何答复。参与者具有种族多样性（40.3％来自少数民族背景），59.1%来自两个最贫困的五分之一。对套件完成的信心差异，如果使用Pearson的χ2分析评估HPV阳性,则对检测结果的信任和参加随访检测的意向.二元逻辑回归模型探讨了未来筛查选择和尿液与阴道自采样的偏好的预测因素。
结果：大多数成套者报告了对自我抽样的高信心（82.6％）和对结果的高信任（79.9％），但是经历因种族和筛查状况而异。大多数自由文本评论都是积极的，但有些人报告使用该设备时遇到了困难，疼痛或不适。大多数女性将来会选择自我抽样(71.3%vs.临床医生进行的测试为10.4％），并且更常被少数族裔群体喜欢，逾期未交的安检人员，从不参加。尿液自检优于阴道检查(41.9%vs.15.4%），尤其是亚洲女性，黑人或其他种族背景。
结论：Kit-completers很有信心，发现测试很容易完成，并信任自采样结果。然而,经历因种族而异，一些妇女强调了使用工具包的困难。大多数女性将来更喜欢自我取样，但这不是一个普遍的偏好，所以提供一个选择将是重要的。
■我们在问卷设计中没有直接的患者和公众参与和参与（PPIE）。然而,患者和公众代表参与了YouScreen试验的设计,并审查了更广泛的研究材料(例如参与者信息表).
背景：这项问卷调查被嵌入在YouScreen试验中。YouScreen试用版的协议可在https://www上获得。isrctn.com/ISRCTN12759467.美国国立卫生研究院43临床研究网络（NIHRCRN）中央投资组合管理系统（CPMS）ID为4441934。
方法：在英国的YouScreen自抽样试验中嵌入了邮政问卷：32.5％（2712/8338）的试剂盒完成者返回了调查。鼓励Kit非完成者返回问卷，但没有收到任何答复。参与者具有种族多样性（40.3％来自少数民族背景），59.1%来自两个最贫困的五分之一。对套件完成的信心差异，如果使用Pearson的χ2分析评估HPV阳性,则对检测结果的信任和参加随访检测的意向.二元逻辑回归模型探讨了未来筛查选择和尿液与阴道自采样的偏好的预测因素。
结果：大多数成套者报告了对自我抽样的高信心（82.6％）和对结果的高信任（79.9％），但是经历因种族和筛查状况而异。大多数自由文本评论都是积极的，但有些人报告使用该设备时遇到了困难，疼痛或不适。大多数女性将来会选择自我抽样(71.3%vs.临床医生进行的测试为10.4％），并且更常被少数族裔群体喜欢，逾期未交的安检人员，从不参加。尿液自检优于阴道检查(41.9%vs.15.4%），尤其是亚洲女性，黑人或其他种族背景。
结论：Kit-completers很有信心，发现测试很容易完成，并信任自采样结果。然而,经历因种族而异，一些妇女强调了使用工具包的困难。大多数女性将来更喜欢自我取样，但这不是一个普遍的偏好，所以提供一个选择将是重要的。
■我们在问卷设计中没有直接的患者和公众参与和参与（PPIE）。然而,患者和公众代表参与了YouScreen试验的设计,并审查了更广泛的研究材料(例如参与者信息表).
背景：这项问卷调查被嵌入在YouScreen试验中。YouScreen试用版的协议可在https://www上获得。isrctn.com/ISRCTN12759467.美国国立卫生研究院43临床研究网络（NIHRCRN）中央投资组合管理系统（CPMS）ID为4441934。
